RAG 06
Alternative Names: RAG-06Latest Information Update: 03 Feb 2023
At a glance
- Originator Ractigen Therapeutics
- Class RNA
- Mechanism of Action Gene expression stimulants; SMN complex protein expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Spinal muscular atrophy
Most Recent Events
- 13 Jan 2023 RAG 06 is available for licensing as of 13 Jan 2023. https://www.ractigen.com/industrial-partnerships/ (Ractigen Therapeutics website, January 2023)
- 13 Jan 2023 Early research in Spinal muscular atrophy in China (Parenteral) (Ractigen Therapeutics pipeline, January 2023)